---
title: "Hengrui Medicine Gets Approval for Spondyloarthritis Clinical Trials"
date: "2025-02-14 10:24:34"
summary: "Jiangsu Hengrui Medicine  obtained approval from China's drug administrator to conduct clinical trials of funaqizumab injection for radiologically negative axial spondyloarthritis, according to a Thursday filing with the Shanghai bourse. Shares of the company rose 1% in recent trade."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Jiangsu Hengrui Medicine obtained approval from China's drug administrator to conduct clinical trials of funaqizumab injection for radiologically negative axial spondyloarthritis, according to a Thursday filing with the Shanghai bourse.

Shares of the company rose 1% in recent trade.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250213:G2467704:0/)
